The Feinstein Institutes for Medical Research

The Feinstein Institutes for Medical Research serves as the research arm of Northwell Health, with a core mission to produce knowledge that cures disease and to bridge the gap between biomedical research and patient care. Headquartered in Manhasset, New York, the Institutes aim to be a global leader in molecular medicine and a leading institution for the education of disease-focused molecular scientists.

The Institutes conduct extensive research across a broad spectrum of medical fields, including molecular medicine, genetics, cancer, neuroscience, behavioral science, and bioelectronic medicine. Its structure comprises six specialized institutes: Behavioral Science, Bioelectronic Medicine, Cancer Research, Health System Science, Molecular Medicine, and Translational Research. Operating 50 research labs and managing between 2,500 and 3,000 clinical research studies, the Feinstein Institutes employs 5,000 to 6,300 professional and support staff. It also hosts the Elmezzi Graduate School of Molecular Medicine, offering advanced education in the field.

Under the leadership of President and CEO Kevin J. Tracey, MD, the Feinstein Institutes continues to achieve notable advancements. In October 2024, it established the Institute of Translational Research, supported by a $5 million gift from the Karches family. Scientists at the Institutes unveiled a novel drug discovery strategy for sepsis and rheumatoid arthritis in February 2026. The organization is widely recognized as a global scientific leader in bioelectronic medicine, an innovative field that integrates molecular medicine, neuroscience, and biomedical engineering to develop device-based therapies.